-- Collaboration investigates enhanced manufacturing of AAV and lentiviral 
vectors to improve quality and productivity for gene therapy and vaccine 
developers


Albumedix Ltd. ('Albumedix') (https://albumedix.com/ ), an emerging leader in 
the enablement of advanced therapies and recognized global leader in 
recombinant human albumin (rHA) has today announced an extension to its 
research collaboration with Cobra Biologics, the gene therapy division of 
Cognate BioServices, a Charles River Laboratories International, Inc. company. 
The research collaboration focuses on process optimization and stability 
enhancement in scale-up manufacturing of AAV and lentiviral vectors through 
Albumedix' proprietary recombinant human albumin-based product. 

Logo - https://mma.prnewswire.com/media/1498257/Albumedix_COBRA_Logo.jpg 

Additionally, the collaboration aims to advance both up-stream and down-stream 
processing of AAV and lentiviral vector manufacturing, including formulation 
development for long-term stability. 

The advanced therapy space is a fast-moving industry with new innovative and 
transformative therapies entering the clinic every day. To increase the chance 
of success and broaden patient availability of these therapies, there is a 
growing need to ensure robust, scalable and economically viable production.

Since 2019, Cobra Biologics and Albumedix have jointly been engaged in work on 
optimizing viral vector manufacturing and production to improve quality and 
productivity for gene therapy and vaccine developers. The current collaboration 
is an extension of the 2019 research collaboration agreement and contemplates 
that both companies further solidify their commitment to a shared goal of 
enabling advanced therapy and biopharmaceutical developers to reach patients 
worldwide with more scalable therapies.  

Jonas Skjodt Moller, CEO, Albumedix, commented: "We are delighted to have found 
a research partner in Cobra, who are as committed as we are in applying 
enabling innovation to push the industry forward. With a mission to empower 
excellence in advanced therapies, we invest and partner to be at the scientific 
forefront, and we look forward to further combine our in-house expertise and 
unique stability enhancing benefits of our recombinant human albumin with 
Cobra's viral vector production platform."

Dr Daniel Smith, Executive Director of Global Cell & Gene Therapy Portfolio, 
Charles River said: "Viral vector manufacturing presents a challenge for gene 
therapy and vaccine developers. This collaboration agreement aims to improve 
the manufacturing of viral vectors through a combination of our own expertise 
alongside that of Albumedix and in particular their recombinant human albumin 
products. We are excited to embark on this research project with Albumedix to 
optimize viral vector manufacturing to ensure supply can meet the growing 
demand of gene therapies."
 
SOURCE  Albumedix Ltd.